Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

A review and update on orphan drugs for the treatment of noninfectious uveitis.

You C, Sahawneh HF, Ma L, Kubaisi B, Schmidt A, Foster CS.

Clin Ophthalmol. 2017 Jan 31;11:257-265. doi: 10.2147/OPTH.S121734. eCollection 2017. Review.

2.

Extraintestinal Manifestations of Inflammatory Bowel Disease.

Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G.

Inflamm Bowel Dis. 2015 Aug;21(8):1982-92. doi: 10.1097/MIB.0000000000000392. Review.

3.

Update on the therapy of Behçet disease.

Saleh Z, Arayssi T.

Ther Adv Chronic Dis. 2014 May;5(3):112-34. doi: 10.1177/2040622314523062. Review.

4.

Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.

Pasadhika S, Rosenbaum JT.

Biologics. 2014 Feb 15;8:67-81. doi: 10.2147/BTT.S41477. eCollection 2014. Review.

5.

Birdshot uveitis: current and emerging treatment options.

Menezo V, Taylor SR.

Clin Ophthalmol. 2014;8:73-81. doi: 10.2147/OPTH.S54832. Epub 2013 Dec 18. Review.

6.

Ex-vivo tolerogenic F4/80⁺ antigen-presenting cells (APC) induce efferent CD8⁺ regulatory T cell-dependent suppression of experimental autoimmune uveitis.

Hsu SM, Mathew R, Taylor AW, Stein-Streilein J.

Clin Exp Immunol. 2014 Apr;176(1):37-48. doi: 10.1111/cei.12243.

7.

Behcet's disease: systemic and ocular manifestations.

Paovic J, Paovic P, Sredovic V.

Biomed Res Int. 2013;2013:247345. doi: 10.1155/2013/247345. Epub 2013 Oct 3.

8.

Correlation between Ocular Manifestations and Their Complications as Opposed to Visual Acuity and Treatment in Behcet's Disease.

Paovic J, Paovic P, Sredovic V.

Autoimmune Dis. 2013;2013:842673. doi: 10.1155/2013/842673. Epub 2013 Aug 29.

9.

Medical management of uveitis - current trends.

Babu K, Mahendradas P.

Indian J Ophthalmol. 2013 Jun;61(6):277-83. doi: 10.4103/0301-4738.114099. Review.

10.

Infliximab therapy for hepatic and intestinal sarcoidosis.

Te HS, Campbell L, Chohan S.

Gastroenterol Hepatol (N Y). 2007 Jun;3(6):447-52. No abstract available.

11.

Biologic agents in inflammatory eye disease.

Posarelli C, Arapi I, Figus M, Neri P.

J Ophthalmic Vis Res. 2011 Oct;6(4):309-16.

12.

Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients.

Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassarà E, Susini M, Lenzetti I.

Biologics. 2012;6:5-12. doi: 10.2147/BTT.S27343. Epub 2011 Dec 29.

13.

Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis.

Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M.

Graefes Arch Clin Exp Ophthalmol. 2012 May;250(5):713-20. doi: 10.1007/s00417-011-1844-0. Epub 2011 Nov 27.

14.

Emerging role of antioxidants in the protection of uveitis complications.

Yadav UC, Kalariya NM, Ramana KV.

Curr Med Chem. 2011;18(6):931-42. Review.

15.
16.

Barrier dysfunction of the corneal endothelium in response to TNF-alpha: role of p38 MAP kinase.

Shivanna M, Rajashekhar G, Srinivas SP.

Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1575-82. doi: 10.1167/iovs.09-4343. Epub 2009 Sep 24.

17.

Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis.

Callejas-Rubio JL, López-Pérez L, Ortego-Centeno N.

Ther Clin Risk Manag. 2008 Dec;4(6):1305-13.

18.

Adalimumab: a new modality for Behçet's disease?

van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM.

Ann Rheum Dis. 2007 Apr;66(4):565-6. Epub 2006 Nov 23. No abstract available.

19.

TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage.

Vinores SA, Xiao WH, Shen J, Campochiaro PA.

J Neuroimmunol. 2007 Jan;182(1-2):73-9. Epub 2006 Nov 14.

20.

Adalimumab in the therapy of uveitis in childhood.

Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M.

Br J Ophthalmol. 2007 Mar;91(3):319-24. Epub 2006 Oct 11.

Supplemental Content

Support Center